Worg Pharma to Acquire Apitope

Hangzhou, China and Diepenbeek, Belgium, (August 18, 2021): Worg Pharmaceuticals (Hangzhou) Co., Ltd (“Worg”), a clinical stage biopharmaceutical company developing new treatments for allergy and Apitope International NV (“Apitope”), a clinical stage biotech company focusing on autoimmune diseases, today announce that they have entered into an asset purchase agreement (the “Agreement”) under which Worg will acquire Apitope’s proprietary platform and therapeutic pipeline. Apitope’s innovative pipeline consists of clinical, preclinical and discovery stage assets for the treatment of a range of autoimmune diseases with significant unmet medical need.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...